← Leaderboards
Grace R Anderson
Duke University
$143,790
Attributed
$143,790
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $71.5K · FY2017–19$100K$75K$50K$25K$0
'17
'18
'19
Funding mix
By agency
NIH$143,790 · 2
By mechanism
F99$72,240 · 1
K00$71,550 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Sheila Collins$15,347,398
- Mark N Feinglos$8,642,419
- Louis M Luttrell$9,404,582
- Mikhail Nikiforov$14,564,827
- Ann Marie Pendergast$20,201,860
Others in their field
Other Emerging Leaders on “Antibiotics”
- Urs Ochsner · Crestone, Inc.$36,950,837
- Ryan Cirz · Revagenix, Inc.$35,410,554
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$24,789,028
- Bruce Blough · Research Triangle Institute$19,637,160
- Thomas Dick · Rbhs-New Jersey Medical School$15,241,285
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$13,685,544
Research focus
AntibioticsApoptosisApoptoticArchitectureAreaBacteriaBaseBcl1 OncogeneBcl2 GeneBypassCancer CellCancer GenomicsCancer SubtypesCancer TherapyCancer TypeCell DeathCell GrowthCell PhysiologyCellsCell SurvivalClinical ResearchClinical TrialsCombinatorialAntibiotic Resistance
Grant awards (3)
Unmasking targetable dependencies in cancer with intrinsic or acquired resistance to anti-cancer therapies$71,550
K00 · FY2019 · CA · contact PI
Unmasking targetable dependencies in cancer with intrinsic or acquired resistance to anti-cancer therapies$35,610
F99 · FY2018 · CA · contact PI
Unmasking targetable dependencies in cancer with intrinsic or acquired resistance to anti-cancer therapies$36,630
F99 · FY2017 · CA · contact PI